North Carolina 2023-2024 Regular Session

North Carolina House Bill H35

Introduced
1/30/23  
Refer
1/31/23  
Report Pass
2/14/23  
Refer
2/14/23  
Report Pass
2/21/23  
Engrossed
2/27/23  

Caption

Expand Definition of Opioid Antagonist

Impact

The passage of HB 35 would significantly impact North Carolina's public health framework surrounding substance use and overdose prevention. It would enhance the capabilities of syringe exchange programs by ensuring they have the necessary medications available to effectively respond to opioid overdoses. Furthermore, this expansion in definition emphasizes the state's commitment to addressing public health issues related to drug misuse and overdose, providing a more comprehensive approach to life-saving interventions.

Summary

House Bill 35 aims to expand the state's definition of opioid antagonist to include all opioid antagonists that are approved by the federal Food and Drug Administration (FDA) for the treatment of drug overdoses. This legislative change seeks to enhance the ability of needle and hypodermic syringe exchange programs to use a broader range of opioid antagonists in their efforts to combat the ongoing opioid crisis. By allowing these programs to utilize all FDA-approved opioid antagonists, the bill aims to improve access to life-saving medications for individuals at risk of overdose.

Sentiment

The overall sentiment surrounding HB 35 appears to be positive, particularly among public health advocates and organizations focused on harm reduction strategies. Proponents argue that this bill represents a proactive step in combating the opioid epidemic, as it increases accessibility to vital medications. However, opponents may raise concerns about the broader implications of syringe exchange programs and their role in the community, indicating that there may still be some contention regarding the implementation and perceived effectiveness of such programs.

Contention

While the bill has garnered general support, there may be notable points of contention regarding the operational aspects of syringe exchange programs and their community acceptance. Some stakeholders might question the impact of such programs in preventing drug-related harm versus potential concerns about enabling substance use. Therefore, ongoing discussions in legislative and community forums could shape the future implementation and modifications of syringe exchange initiatives within the state.

Companion Bills

No companion bills found.

Similar Bills

CA AB1166

Liability for opioid antagonist administration.

CA AB24

Emergency response: opioid antagonist kits.

CO HB1037

Substance Use Disorders Harm Reduction

MA H1337

Relative to opioid use disorder treatment and rehabilitation coverage

CA SB234

Opioid antagonists: stadiums, concert venues, and amusement parks.

CA AB2998

Opioid overdose reversal medications: pupil administration.

WY SF0101

Epinephrine and naloxone administration authority.

TX HB2411

Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.